X

Company

About NIMGenetics

About NIMGenetics

NIMgenetics Biomedical company

NIMGenetics is a privately owned Spanish biomedical company specializing in the design and commercialization of products and services for clinical genetic diagnosis. We develop exclusive genomic products and services essentially based on two technologies; microarrays and Next-generation sequencing. We have expanded the value of our high-performance genomic products and services to the international market, becoming a top leader in genomic analysis and human genetic diagnostics.

Our Credentials
COMMITMENTS
We fulfill our commitments with health specialists, patients and companies with whom we develop strategic alliances by building long-term links.
EXPERTISE
We know the health market in detail and particularly the sector specializing in clinical genetics and biomedical research.
R+D
We offer an outstanding innovative capacity to develop and apply genomic technologies to the fields of medicine and biomedical research.
QUALITY
We provide quality to our products, services and processes, through policies of continuous improvement. 

Business Model

NIMGenetics’ business model is based upon two fundamental platforms:

1.- NIMGenetics has a professional scientific and medical multidisciplinary and innovative team with a proven track-record in applying new genomic technologies to medicine and research, and a solid experience in analysis and interpretation of genomic data.

2.- It attracts the talent of professional experts in fields such as administration, management, and corporate development based on in-depth knowledge of business, with the aim of identifying and capitalizing market opportunities in an innovative and efficient manner.

The resources applied to genetic diagnostic services and to external R+D services (genetic expression projects, Next Generation Sequencing, experimental genetics) generate a cash-flow which allows us to invest in new technologies, giving us a competitive advantage over other companies in this sector. The new products broaden our portfolio of customers, which allows us to keep innovating new diagnostic products with a high commercializing potential. This value chain becomes a circle in which continuous R+D+I plays a fundamental role in generating new developments, facilitating access to new markets and accelerating our expansion and miNIMizing the risk of technologic stagnation.

Fundamental Pillars

Presenting genetic diagnostic services using the latest technology of microarrays and NGS offered to medical professionals in the fields of Gynecology, Neuropediatrics, Oncology, Cell Therapy and Cardiology.

Introducing Consultancy and R+D project support services to national and international centers that do not have genomic tools or a specific know-how.

Developing, designing and commercializing proprietary microarrays for users and healthcare professionals with direct patient care. This means improving the expansion and scalability of the company´s business, recruiting prestigious professionals onto our management team with a broad experience in the health sector.

Internationalizing genetic diagnostic services and establishing consortia and corporate joint-ventures.

Establishing alliances with multinationals technologies: Agilent Technologies, Life Technologies, BGI, etc.

Acquiring small and medium-sized companies with genetic services.

International

NIMGenetics is a Spanish leading European company specializing in genetic diagnosis, using DNA microarrays, Next Generation Sequencing and FISH probes, all of them with medical applications in different areas (Gynecology, Paediatrics and Neuropaediatrics, Oncohematology, etc.)  We consider our presence in foreign markets as a strategic cornerstone. This is the reason why we started our international expansion phase in the year 2016.

Our strategic goal is to provide medical specialists our diagnostic tools and our knowledge of the human genome in benefit of  their patients.

In addition NIMGenetics is investing to reach markets that we understand can be the spearhead of our positioning and international development. By this way, we want that a greater number of physicians and patients can benefit from our diagnosis.

Nowadays, NIMGenetics is present in Brazil with a integral laboratory focused in patients and a team of geneticists highly qualified. Futhermore, we have collaborators in Mexico, Colombia, Chile, Peru, Paraguay, Uruguay, UK, Portugal and India.

NIMGenetics has development an investment plan for the next three years with this goals:

  • Increase the inversion in our actual markets to consolidate the enterprise position
  • Introduces our services in new markets
mapa-nim

Activity

2014
Latin America, India and Portugal

International expansion to Latin America India and Portugal

2013
Starting up internacionalization process

In collaboration with the Complutense University of Madrid, it introduces the Next Generation Sequencing service OncoNIM® Seq 50 for the detection of 2800 oncologic mutations, and develops the Sudden Death Mutations test CardioNIM®.

NIMGenetics is invited by the Beijing Genomics Institute of Senzhen, China, a world leader in genomics, to the Non Invasive Fetal Diagnostics International Congress in Prague.

TrisoNIM® is an awardee of The Awards to the 100 best ideas of 2012, given by the magazine Actualidad Económica, in its health category.    

It participates in the BioEurope Fair, where it establishes effective contacts with different national and international companies.

The Management team is invited by Agilent Technologies to its headquarters in California as expert advisers in situ Hybridization technology (FISH).  

Signs a bidirectional collaboration agreement with 52 clinical analysis laboratories in provinces throughout the Spanish territory.

Initiates an agreement with several private medical insurance companies as a genetic test-provider.

Begins international expansion in Mexico.

Signs a mandate with the company Strategic Karma, searching for Joint Venture opportunities for expansion in India.

Creates a commercial network of product specialists, and a national network of commercial agents. Introduces the position of Key Account Manager.

Begins its UNE EN ISO 9001:2008 and UNE EN ISO 15189:2012 certification process.

Appointment of NIMGenetics’ Laboratory Manager as Chairman of the Spanish Human Genetics Association (AEGH).

Design and development of the NIMGenetics new corporate WEB site.

 

 

2012
Development, Registration and commercialization

Develops and registers the KaryoNIM® Autism 180K, KaryoNIM®Stem Cells, OncoNIM® Familial Cancer and OncoNIM®Diagnostic Cancer Arrays.

Wins the IE Venture Day prize, in the category of best off-line company with greatest potential for growth in Spain.

Receives authorization from Agilent Technologies for direct sales of its microarrays under the name of NIMGenetics, after signing a reseller agreement for Europe, South America and South Africa.

Commercializes for the first time in Spain the TrisoNIM® test, in collaboration with the multinational Beijing Genomics Institute (BGI), for the detection of Down, Edwards and Patau Syndromes in maternal blood.

It participates in BioSpain, presenting the KaryoNIM®, OncoNIM® and TrisoNIM® tests, and initiates a mass media campaign at a national level scheduled for two years.

It incorporates two new positions, a Commercial Manager and a Business Development Manager

2011
KaryoNIM® Development

It develops and registers the constitutional KaryoNIM® 60K Array and a new version of KaryoNIM® prenatal 60K Array.

It gains 1st place in the category of biotechnology and 6th place overall, in the national contest of technology-based companies Emprendedor XXI (sponsored by La Caixa Capital Risc and ENISA).

It is selected as a PIPE company by the Madrid Chamber of Commerce and ICEX (Foreign Trade Institute) for its internationalization potential.

Obtains the Certification of Quality from the Cytogenetics European Quality Association, as a certified laboratory of genetic diagnosis through CGH Arrays.

2010
Best SME Growth Project Award

It is awarded “The Small & Medium Sized Enterprises´ best project for growth”, prize at the selective Banespyme Orange competition, promoted by the IE Business School.

It is the only company in Southern Europe with official recognition as a Certified Service Provider of Agilent Technologies.

Obtains the INNPACTO-ASCIVAR Project in collaboration with the company TIGENIX (previously known as Cellerix), from the Genetrix group, for the design of a genetic diagnostics array of stem cells.

It develops and registers the KaryoNIM® 15K Array for diagnosis of 96 prenatal genetic syndromes.

2008 2009
Registration & Setting Up

NIMGenetics was founded in 2008, and certified by the Heath Department of the Community of Madrid as a Center of Analytical Diagnostics with a Genetics Unit. During 2009 it matures into a pioneering company and a leader in Spain in genomic analysis by Array CGH for genetic diagnostics.

It is endorsed by CDTI’s NEOTEC program for developing an invasive prenatal genetic diagnostics test that detects 96 genetic syndromes through the KaryoNIM® Prenatal Array.

Partnership

karma

Strategic Karma

Signs a mandate with the company Strategic Karma, searching for Joint Venture opportunities for expansion in India.

privadas

Private Medical Insurance Companies

Initiates an agreement with several private medical insurance companies as a genetic test-provider (2013)

medicos

Bidirectional Collaboration

Signs a bidirectional collaboration agreement with 52 clinical analysis laboratories in provinces throughout the Spanish territory

Logo_UCM

UCM

In collaboration with the Complutense University of Madrid, it introduces the Next Generation Sequencing service OncoNIM®Seq 50 (2013)

bgi

Beijing Genomics Institute

Commercializes for the first time in Spain the TrisoNIM® test, in collaboration with the multinational Beijing Genomics Institute (BGI), for the detection of Down, Edwards and Patau Syndromes in maternal blood. (2012)

agilent

Agilent Technologies

Agreement with Agilent Technologies for direct sales of its microarrays under the name of NIMGenetics after signing a reseller agreement for Europe, South America and South Africa (2012).

espana

Retos-Colaboración

Obtains the RETOS-COLABORACIÓN Project in collaboration with the company AGLARIS CELL and the University of Extremadura for the genetic instability control of stem cell, grown in bioreactor, products.

Social Responsibility

NIMGenetics actively contributes to social and economic progress of our society as well as to improving the quality of environment.  On a voluntary and proactive basis, we assume our share of responsibility associated with developing our activity in the field of health, society and environment.

For us, globalization not only implies commercial or financial aspects, but also integrates dimensions of social transformation of greater scope. Our contribution to society and to social and global markets requires us to reach a high level of competitiveness, which, within the framework of sustainable development, allows us to achieve goals of high social impact, such as innovation and technology transfer in healthcare.

We promote innovating conciliation measures at work with a view to achieve the best possible working environment for our employees and collaborators.

We have a strong commitment to quality. Continuous improvement of our products, services and processes is a constant feature in our company. The UNE EN ISO 9001:2008 Certification and the UNE EN ISO 15189:2012 vouch for our commitment to quality.

Accreditations and Collaborations

Accreditations
AEGH
Holds the Chairmanship of the Spanish Association of Human Genetics (AEGH), through its professional staff (2013)
2

TrisoNIM is an awardee of The Awards to the 100 best ideas of 2012, given by the magazine Actualidad Económica, in its health category (2013)

3

Sole Certified Service Provider of Agilent Technologies for Southern Europe (2010)

4

Certificate of Quality  from the Cytogenetics European Quality Association, as a certified laboratory for  genetic diagnostics by Arrays CGH (2011)

5
Member of the European Cytogenetics Association (ECA), through its professional staff (ECA).

Agreement with Agilent Technologies for direct sales of its microarrays under the name of NIMGenetics after signing a reseller agreement for Europe, South America and South Africa(2012)

6

Wins the IE Venture Day prize, in the category of best off-line company with greatest potential for growth in Spain.

7

Member of the Evaluation Panel of the Leukemia & Lymphoma Research Society, through its professional staff (2012)

9

NIMGenetics is the first Spanish company obtaining certification as Certified Service Provider of Life Technologies Corporation for exome sequencing (2013)

NEWSLETTER NIMGENETICS
Are you interested in receiving our newsletter?